Novel cardiac myosin activators for acute heart failure

Expert Opinion on Investigational Drugs

Volumn 16, Issue 10, 2007, Pages 1541-1548

  Bragadeesh, Thanjavur K M ^a   Mathur, Gaurav ^a   Clark, Andrew L ^a   Cleland, John G F ^a  

^a CASTLE HILL HOSPITAL   (United Kingdom)

Author keywords

Crossbridge cycle; Heart failure; Inotropes; Myosin activators

Indexed keywords

ADENOSINE TRIPHOSPHATE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CALCIUM; CARDIAC MYOSIN ACTIVATOR; CARDIOTONIC AGENT; CATECHOLAMINE; CK 0689705; CK 1122534; CK 1213296; CK 1827452; CYCLIC AMP; INOTROPIC AGENT; ISOPRENALINE; MILRINONE; MYOSIN; MYOSIN ADENOSINE TRIPHOSPHATASE; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; TROPONIN; UNCLASSIFIED DRUG; CARDIAC MYOSIN;

ACUTE HEART FAILURE; CLINICAL TRIAL; CONCENTRATION RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME DEGRADATION; HEART CONTRACTION; HEART OUTPUT; HEART PALPITATION; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HUMAN; MAXIMUM TOLERATED DOSE; MYOFILAMENT; NONHUMAN; REVIEW; SIDE EFFECT; THORAX PAIN; ANIMAL; CONGESTIVE HEART FAILURE; PHASE 1 CLINICAL TRIAL; PHYSIOLOGY;

ANIMALS; CARDIAC MYOSINS; CARDIOTONIC AGENTS; CLINICAL TRIALS, PHASE I; HEART FAILURE, CONGESTIVE; HUMANS; MYOCARDIAL CONTRACTION;

EID: 35248864000     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.16.10.1541     Document Type: Review

References (58)

1. NIEMINEN MS, BOHM M, COWIE MR et al.: Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the task force on acute heart failure of the European society of cardiology. Eur. Heart J. (2005) 26(4):384-416.
2. BANERJEE P, CLARK AL, NIKITIN N, CLELAND JG: Diastolic heart failure. Paroxysmal or chronic? Eur. J. Heart Fail, (2004) 6(4):427-431.
3. ROGUIN A, BEHAR D, BEN AMI H et al.: Long-term prognosis of acute pulmonary oedema - an ominous outcome. Eur. J. Heart Fail. (2000) 2(2):137-144.
4. RAMIREZ A, ABELMANN WH: Cardiac decompensation. N. Engl. J. Med. (1974) 290(9):499-501.
5. LEVY D, KENCHAIAH S, LARSON MG et al.: Long-term trends in the incidence of and survival with heart failure. N. Engl. J. Med. (2002) 347(18):1397-1402.
6. CLELAND JG, CLARK AL: Delivering the cumulative benefits of triple therapy to improve outcomes in heart failure: too many cooks will spoil the broth. J. Am. Coll. Cardiol. (2003) 42(7):1234-1237.
7. SWEDBERG K, CLELAND J, DARGIE H et at.: Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the task force for the diagnosis and treatment of chronic heart failure of the European society of cardiology. Eur. Heart. J. (2005) 26(11):1115-1140.
8. PITT B, ZANNAD F, REMME WJ et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone evaluation study investigators. N. Engl, J. Med. (1999) 341(10):709-717.
9. Effects of enalapril on mortality in severe congestive heart failure. Results of the cooperative North Scandinavian enalapril survival study (CONSENSUS). The CONSENSUS trial study group. N. Engl. J. Med. (1987) 316(23):1429-1435.
10. PACKER M, COATS AJ, FOWLER MB et al.: Effect of carvedilol on survival in severe chronic heart fidure. N. Engl. J. Med. (2001) 344(22):1651-1658.
11. CLELAND JG, DAUBERT JC, ERDMANN E et al.: The effect of cardiac resynchronization on morbidity and mortality in heart failure. N. Engl. J. Med. (2005) 352(15):1539-1549.
12. SACKNER-BERNSTEIN JD, KOWALSKI M, FOX M, AARONSON K: Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA (2005) 293(15):1900-1905.
13. THACKRAY S, EASTHAUGH J, FREEMANTLE N, CLELAND JG: The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis. Eur J. Heart Fail. (2002) 4(4):515-529.
14. O'CONNOR CM, GATTIS WA, URETSKY BF et al.: Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan international randomized survival trial (FIRST). Am. Heart J. (1999) 138(1 P 1):78-86.
15. ABRAHAM WT, ADAMS KF, FONAROW GC et al.: In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the acute decompensated heart failure national registry (ADHERE). J Am. Coll. Cardiol. (2005) 46(1):57-64.
16. FOLIATH F, CLELAND JG, JUST H et al.: Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet (2002) 360(9328):196-202.
17. KASS DA, SOLARO RJ: Mechanisms and use of calcium-sensitizing agents in the failing heart. Circulation (2006) 113(2):305-315.
18. MOISEYEVS, PODER P, ANDREJEVS N et al.: Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular fiilure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSIAN). Eur. Heart J. (2002) 23(18):1422-1432.
19. PARISSIS JT, FARMAKIS D, NIEMINEN M: Classical inotropes and new cardiac enhancers. Heart Fail. Rev. (2007) 12(2):149-156.
20. MEBAZAA A, NIEMINEN MS, PACKER M et al.: Levosimendan versus dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA (2007) 297(17):1883-1891.
21. TOBACMAN LS: Thin filament-mediated regulation of cardiac contraction. Ann. Rev. Physiol, (1996) 58:447-481.
22. GREASER ML, GERGELY J: Purification and properties of the components from tropinin. J Biol. Chem. (1973) 248:2125-2133.
23. COOKE R. Actomyosin interaction in striated muscle. Physiol. Rev. (1997) 77:671-697.
24. HOLMES KC: Muscle proteins - their actions and interactions. Curr. Opin. Struct. Biol. (1996) 6:781-789.
25. PATE E, COOKE R: A model of crossbridge action: the effects of ATE, ADP and Pi. J. Muscle Res. Cell Motil. (1989) 10:181-196.
26. GEEVES NM CONIBEAR PB: The role of three-state docking of myosin S1 with actin in force generation. Biopbys. J. (1995) 68:S194-S199.
27. KAWAI M, GUTH K, WINNIKES Y, HAIST C, RUEGG JC: The effect of inorganic phosphate on the ATP hydrolysis rate and the tension transients in chemically skinned rabbit psoas fibers. Pflugers Arch. (1987) 408:1-9.
28. COOKE R. The actomyosin engine. FASEB J.(1995) 9(8):636-642.
29. GORDON AM, HOMSHER E, REGNIER M: Regulation of contraction in striated muscle. Physiol. Rev. (2000) 80:853-924.
30. HAJJAR RJ, GWATHMEY JK: Cross-bridge dynamics in human ventricular myocardium. Regulation of contractility in the failing heart. Circulation(1992) 86:1819-1826.
31. RUF T, SCHULTE-BAUKLOH H, LUDEMANN J et al.: Alterations of cross-bridge kinetics in human atrial and ventricular myocardium. Cardiovasc. Res. (1998) 40:580-590.
32. HASENFUSS G, MULIERI LA, LEAVITT BJ, ALLEN PD, HAEBERLE JR, ALPERT NR: Alteration of contractile function and excitation-contraction coupling in dilated cardiomyopathy. Circ, Res. (1992) 70:1225-1232.
33. ANDERSON PA, MALOUF NN, OAKELEY AE, PAGANI ED, ALLEN PD: Troponin T isoform expression in humans. A comparison among normal and failing adult heart, fetal heart, and adult and fetal skeletal muscle. Circ. Res. (1991) 69:1226-1233.
34. BODOR GS, OAKELEY AE, ALLEN PD, CRIMMINS DL, LADENSON JH, ANDERSON PA: Troponin I phosphorylation in the normal and failing adult human heart. Circulation (1997) 96:1495-1500.
35. FELDMAN MD, COPELAS L, GWATHMEY JK et al.: Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure. Circulation (1987) 75:331-339.
36. ZHAO M, SONNENBLICK EH, ZHANG H, ENG C: Increase in myofilament separation in the 'stunned' myocardium. J. Mol. Cell Cardiol. (1992) 24:269-276.
37. DECKER RS, DECKER ML, KULIKOVSKAYA I et al.: Myosin-binding protein C phosphorylation, myofibril structure, and contractile function during low-flow ischemia. Circulation (2005) 111(7):906-912.
38. BRAGADEESH T, JAYAWEERA AR, PASCOTTO M et al.: Post-ischemic myocardial dysfunction ('stunning') is caused by myofibrillar edema. Circulation (2005) 112:11-514 (Abstract).
39. GEENEN DL, MALHOTRA A, SCHEUER J: Regional variation in rat cardiac myosin isoenzymes and ATPase activity aher infarction. Am. J. Physiol. (1989) 256:H745-H750.
40. ALOUSI AA, GRANT AM, ETZLER JR, COFER BR, BEL-KAHN J, MELVIN D: Reduced cardiac myofibrillar Mg-ATPase activity without changes in myosin isozymes in patients with end-stage heart failure. Mol. Cell Biochem. (1990) 96:79-88.
41. PAGANI ED, ALOUSI AA, GRANT AM, OLDER TM, DZIUBAN SW Jr, ALLEN PD: Changes in myofibrillar content and Mg-ATPase activity in ventricular tissues from patients with heart failure caused by coronary artery disease, cardiomyopathy, or mitral valve insufficiency. Circ. Res. (1988) 63:380-385.
42. + activated myosin ATPase activity in ventricular myofibrils from non-failing and diseased human hearts-effects of calcium sensitizing agents MCI-154, DPI 201-106, and caffeine. Mol. Cell Biochem. (2003) 245:77-89.
43. MALIK F, ELIAS KA, FINER JT et al.: Direct activation of cardiac myosin by CK-1827452 improves cardiac function in a dog heart failure model. Presented at National Conference of the Heart Failure Society of America. Boca Raton, USA (18-21 September 2005).
44. YASUDA M, NAKATANI K, MATSUNAGA K, MURAKAMI M, MOMOSE K, OHIZUMI Y: Modulation of actomyosin ATPase by goniodomin A differs in types of cardiac myosin. Eur. J. Pharmacol. (1998) 346:119-123.
45. RODRIGUEZ HM, SYLVESTER S, KAWAS R, MALIK F, SAKOWICZ R: Activation of the cardiac sarcomere by a small molecule agent, CK-1213296. Presented at Biophysical Society Annual Meeting. Salt Lake City, USA (18-22 February 2006).
46. ANDERSON RL, SUEOKA SH, LEE KH et al.: In vitro and in vivo efficacy of the cardiac myosin activator CK-1827452. Presented at National Conference of the American Society of Cell Biology. San Francisco, USA (2005).
47. BAYRAM M, DE LUCA L, MASSIE MB, GHEORGHIADE M: Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes. Am. J. Cardiol. (2005) 96:G47-G58.
48. NIU C, COX D, LEE KH et al.: Cellular responses of the myosin activator CK-0689705 in normal and heart failure models. Presented at National Conference of the American Society of Cell Biology. Seattle, USA (4-8 December 2004).
49. SHEN YT, VATNER SF, MORGANS DJJR, MALIK F: Activating cardiac myosin, a novel inotropic mechanism to improve cardiac function in conscious dogs with congestive heart failure. Presented at Heart Failure Society of America. Seattle, USA (10-13 September 2006).
50. TEERLINK JR: Selective cardiac myosin activator CK-1827452. Presented at Heart Failure Society of America. Seattle, USA (10-13 September 2006).
51. CLELAND JG, COLETTA AP, CLARK AL: Clinical trials update from the heart failure society of America meeting: FIX-CHF-4, selective cardiac myosin activator and OPT-CHE Eur. J. Heart Fail. (2006) 8(7):764-766.
52. CHATTOPADHYAYS,ALAMGIR MF, NIKITIN N, CLARK AL, CLELAND J: Prevalence of intraventricular dyssynchrony increases with stress. Circulation (2005) 112:II-403 (Abstract).
53. NIKOLIC S, YELLIN EL, TAMURA K et al.: Passive properties of canine left ventricle: diastolic stiffness and restoring forces. Circ. Res. (1988) 62:1210-1222.
54. SOLOMON SB, NIKOLIC SD, GLANTZ SA, YELLIN EL: Left ventricular diastolic function of remodeled myocardium in dogs with pacing-induced heart failure. Am. J. Physiol. (1998) 274:H945-H954.
55. WHITE HD, NORRIS RM, BROWN MA, BRANDT PW, WHITLOCK RM, WILD CJ: Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation (1987) 76:44-51.
56. DE SILVA R, NIKITIN NP, WITTE KK et al.: Incidence of renal dysfunction over 6 months in patients with chronic heart failure due to left ventricular systolic dysfunction: contributing factors and relationship to prognosis. Eur. Heart J. (2006) 27(5):569-581.
57. SCHAUB MC, HEFTI MA, ZUELLIG RA, MORANO I: Modulation of contractility in human cardiac hypertrophy by myosin essential light chain isoforms. Cardiovasc. Res. (1998) 37:381-404.
58. MAUGHAN DW: Kinetics and energetics of the crossbridge cycle. Heart Fail. Rev. (2005) 10(3):175-185.